Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.
Albany, NY-based contract manufacturer AMRI has continued its buying spree for more and more diverse manufacturing capacity, and the deals are getting larger. Its latest is a $174 million deal for a drugmaker in Spain that makes specialty APIs and sterile injected drugs.
Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.
AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.
Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.
Contract manufacturer AMRI has been reworking its manufacturing assets, picking up valuable pieces here and there and then sacrificing a less important one as it moves toward contract manufacturing and away from a reliance on royalties. Its most recent earnings suggest the strategy is paying off on the top line at least.
Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.
Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.
U.S. contract manufacturer AMRI says that it will follow through with plans to close its API manufacturing site in Holywell, U.K., a move that will mean the loss of 62 jobs.
Sixty-four jobs are at risk as a result of AMRI's proposal to close an API plant in Wales. A final decision for the plant will come after a consultation with employees and discussions on ways to reduce "redundancies" at the former Excelsyn facility.